Welcome to our dedicated page for BOSTON SCIENTIFIC SEC filings (Ticker: BSX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BOSTON SCIENTIFIC's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BOSTON SCIENTIFIC's regulatory disclosures and financial reporting.
Boston Scientific SVP and Chief HR Officer Miriam O'Sullivan reported several equity compensation transactions dated February 12, 2026. She acquired 961 shares of Boston Scientific common stock at $0.0000 through the exercise of restricted stock units, then had 338 shares withheld at $74.12 per share to cover tax obligations, leaving 15,420 directly held shares plus 1,731 held indirectly by her spouse.
On the derivative side, she exercised 961 restricted stock units, ending with 1,924 restricted stock units directly owned. She also received a new grant of 4,722 restricted stock units and a stock option award for 11,143 shares. The restricted stock units and options vest in four equal annual installments beginning on February 12, 2027, with the earlier RSU grant delivering shares in four equal installments starting February 12, 2025.
Boston Scientific SVP Emily Woodworth reported multiple equity awards and an RSU exercise. On February 12, 2026, she exercised 481 restricted stock units into 481 common shares at an exercise price of $0.0000 and had 242 shares withheld at $74.12 per share to cover tax obligations, leaving 951 common shares directly owned. She also received 6,071 new restricted stock units and a grant of 5,584 stock options with a $74.12 exercise price, each vesting in four equal annual installments starting February 12, 2027.
Boston Scientific executive Padraig Andrew O'Connor, EVP Global Operations, reported several equity compensation transactions dated February 12, 2026. He exercised 1,058 restricted stock units into common shares and had 457 shares withheld at $74.12 per share to cover tax obligations, leaving 4,486 common shares directly owned.
He now directly holds 2,116 restricted stock units from earlier awards. On the same date, he received a new grant of 5,059 restricted stock units and 11,939 stock options. The RSUs and options vest in four equal annual installments beginning on February 12, 2027, with each unit or option tied to one share of common stock.
Boston Scientific EVP and CFO Jonathan Monson reported several equity transactions on February 12, 2026. He exercised 1,154 restricted stock units into common shares at a conversion price of $0.0000, then had 573 common shares withheld at $74.12 per share to cover tax obligations, leaving 35,870 common shares held directly.
Monson also acquired new equity awards. He received 11,805 restricted stock units, each representing one future share of Boston Scientific common stock, and was granted stock options for 27,857 shares. Both the new RSUs and options vest in four equal annual installments beginning February 12, 2027.
Boston Scientific Chairman, President & CEO Michael F. Mahoney reported several equity compensation transactions dated February 12, 2026. He acquired 13,704 shares of common stock through the exercise of restricted stock units at $0.0000 per share, then disposed of 6,626 shares at $74.12 per share to cover tax obligations, leaving 1,418,813 common shares held directly.
Mahoney also received a new grant of 55,652 restricted stock units and a stock option for 131,329 shares with an exercise price of $74.12 per share, both vesting in four equal annual installments beginning February 12, 2027. In addition, 213,679 common shares are held indirectly in a trust.
Boston Scientific EVP & Group President, Cardiology Joseph Michael Fitzgerald reported equity compensation and related share movements. On February 12, 2026, he exercised 3,462 restricted stock units, receiving the same number of Boston Scientific common shares. To cover tax obligations, 1,612 common shares were disposed of at $74.12 per share through share withholding, leaving him with 169,892 common shares held directly. He also received new awards of 18,550 restricted stock units and a stock option for 43,776 shares, each vesting in four equal annual installments beginning on February 12, 2027. Following these transactions, he directly holds 6,924 restricted stock units and 18,550 restricted stock units from the new grant, plus the 43,776-share stock option. An additional 5,234 common shares are reported as held indirectly by his child, and he disclaims beneficial ownership of those shares.
Butcher Arthur C reported multiple insider transaction types in a Form 4 filing for BSX. The filing lists transactions totaling 57,681 shares at a weighted average price of $74.12 per share. Following the reported transactions, holdings were 5,386 shares.
Boston Scientific executive Vance R. Brown, EVP, GC and Corporate Secretary, reported equity compensation changes tied to restricted stock units and options. On February 12, 2026, 1,442 restricted stock units were exercised into 1,442 shares of common stock, and 488 shares were disposed of to cover tax withholding at $74.12 per share.
Following these transactions, Brown directly held 34,405 shares of common stock. He also received new grants of 7,420 restricted stock units and 17,510 stock options with a $74.12 exercise price, each vesting in four equal annual installments beginning February 12, 2027.
Boston Scientific Corporation provides an overview of its global medical device business, strategy and key transactions in its annual report for the year ended December 31, 2025. The company highlights a definitive agreement to acquire Penumbra for $14.500 billion, funded with approximately $11.000 billion of cash and new debt and the balance in stock.
Boston Scientific reports an aggregate market value of common stock held by non‑affiliates of about $158.7 billion based on a $107.41 share price on June 30, 2025, and 1,483,885,456 shares outstanding as of January 30, 2026. Total debt was $11.436 billion as of December 31, 2025. The company employed roughly 59,000 people worldwide at year‑end 2025, with 36 percent of net sales generated outside the U.S.
The report details two completed 2025 acquisitions—Bolt Medical and SoniVie—to expand intravascular and hypertension technologies, and explains a 2023 restructuring program expected to generate annual pre‑tax savings of $350 million to $400 million from total charges of $700 million to $800 million. Extensive risk disclosures cover competition, pricing pressure, regulation, cybersecurity, supply chain, climate and human‑capital challenges.
Boston Scientific Corporation disclosed that director Yoshiaki Fujimori has informed the company he will not stand for re-election at the 2026 Annual Meeting of Stockholders. He has served on the Board since July 2016 and currently chairs the Risk, Science and Technology Committee.
Mr. Fujimori will continue as a director and in his committee roles until the 2026 Annual Meeting. The company states that his decision is not due to any disagreement with the company. The Board and its Nominating and Governance Committee will continue reviewing Board size and composition and may consider adding directors after his departure.